巨噬细胞膜修饰纳米颗粒治疗糖尿病心血管并发症的研究进展

潘昕昀 ,  宋昀键 ,  王中群

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 821 -826.

PDF (2075KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 821 -826. DOI: 10.12092/j.issn.1009-2501.2026.06.011

巨噬细胞膜修饰纳米颗粒治疗糖尿病心血管并发症的研究进展

作者信息 +

Research progress on macrophage membrane nanoparticles in the treatment of diabetic cardiovascular complications

Author information +
文章历史 +
PDF (2123K)

摘要

糖尿病心血管并发症是糖尿病患者死亡的主要原因之一。近年来,纳米颗粒药物递送系统在药物递送领域展现出显著优势,尤其在感染性疾病、癌症以及心血管疾病等疾病治疗中展现出巨大潜力。其中巨噬细胞膜修饰纳米颗粒凭借其出色的免疫逃逸能力和炎症靶向特性,显著增加药物在病变组织的富集,使其成为心血管并发症治疗研究的新方向。本文就巨噬细胞膜修饰纳米颗粒的仿生特性、作用机制及其在糖尿病心血管并发症治疗中的最新研究进展做一综述。重点探讨了该技术在调控炎症反应、缓解氧化应激以及改善内皮功能等方面的机制。旨在为开发针对糖尿病心血管并发症的精准治疗策略提供新的思路。

Abstract

Diabetic cardiovascular complications are one of the main causes of death in diabetic patients. In recent years, nanoparticle drug delivery systems have shown significant advantages in the field of drug delivery, especially in the treatment of infectious diseases, cancer and cardiovascular diseases. Among them, macrophage membrane nanoparticles significantly increase the enrichment of drugs in diseased tissues by virtue of their excellent immune escape ability and inflammatory targeting characteristics, making them a new direction for the treatment of cardiovascular complications. This article reviews the bionic characteristics, mechanism of action of macrophage membrane nanoparticles and the latest research progress in the treatment of diabetic cardiovascular complications. The mechanism of this technology in regulating the inflammatory response, alleviating oxidative stress and improving endothelial function was discussed. The aim is to provide new ideas for the development of precise treatment strategies for diabetic cardiovascular complications.

关键词

糖尿病 / 心血管并发症 / 巨噬细胞膜 / 纳米颗粒 / 药物递送

Key words

diabetes / cardiovascular complications / macrophage membrane / nanoparticles / drug delivery

引用本文

引用格式 ▾
潘昕昀,宋昀键,王中群. 巨噬细胞膜修饰纳米颗粒治疗糖尿病心血管并发症的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(6): 821-826 DOI:10.12092/j.issn.1009-2501.2026.06.011

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Schwarz P. IDF global clinical practice recommendations for managing type 2 diabetes-2025[J].Diabetes Res Clin Pr, 2025, 222 Suppl 1: 112158.

[2]

Wong ND, Sattar N.Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention[J].Nat Rev Cardiol, 2023, 20(10): 685-695.

[3]

Giacco F, Brownlee M. Oxidative stress and diabetic complications[J].Circ Res, 2010, 107(9): 1058-1070.

[4]

Khan AW, Jandeleit-Dahm KAM.Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches[J].Nat Rev Cardiol, 2025, 22(7): 482-496.

[5]

刘刚, 刘明宇, 李修靖, 等. 负载双氢青蒿素的中空介孔二氧化锰纳米颗粒对胰腺癌 BxPC-3 细胞的杀伤效应[J].安徽医学, 2023, 44(6): 623-628.

[6]

Beach MA, Nayanathara U, Gao Y, et al. Polymeric nanoparticles for drug delivery[J].Chem Rev, 2024, 124(9): 5505-5616.

[7]

Wang Y, Zhang K, Li T, et al. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications[J].Theranostics, 2021, 11(1): 164-180.

[8]

Molinaro R, Corbo C, Martinez JO, et al. Biomimetic proteolipid vesicles for targeting inflamed tissues[J].Nat Mater, 2016, 15(9): 1037-1046.

[9]

Gao C, Huang Q, Liu C, et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines[J].Nat Commun, 2020, 11(1): 2622.

[10]

Zhang Y, Jin S, Li D, et al. A Machine-learning-based bibliometric analysis of cell membrane-coated nanoparticles in biomedical applications over the past eleven years[J].Glob Chall, 2023, 7(4): 2200206.

[11]

Zeng R, Lv B, Lin Z, et al. Neddylation suppression by a macrophage membrane-coated nanoparticle promotes dual immunomodulatory repair of diabetic wounds[J].Bioact Mater, 2024, 34: 366-380.

[12]

Rodriguez Y, Wan S, Yang S, et al. Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment[J].J Nanobiotechnol, 2022, 20(1): 542.

[13]

Rodriguez PL, Harada T, Christian DA, et al. Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles[J].Science, 2013, 339(6122): 971-975.

[14]

Li Y, Che J, Chang L, et al. CD47- and integrin α4/β1-co-modified-macrophage-membrane-coated nanoparticles enable delivery of colchicine to atherosclerotic plaque[J].Adv Healthc Mater, 2022, 11(4): e2101788.

[15]

Zhao J, Ling L, Zhu W, et al. M1/M2 re-polarization of kaempferol biomimetic NPs in anti-inflammatory therapy of atherosclerosis[J].J Control Release, 2023, 353: 1068-1083.

[16]

Chen C, Cao J, Gao Y, et al. High glucose promotes macrophage M1 polarization through miR-32/Mef2d/cAMP signaling pathway[J].Genes Dis, 2023, 11(2): 539-541.

[17]

Dong X, Suo Y, Yu J, et al. Biomimetic nanoparticles simultaneously targeting modulation of lipid metabolism and phenotype of macrophages for programmed atherosclerosis management[J].ACS Nano, 2025, 19(28): 25628-25644.

[18]

Chen X, Xie N, Feng L, et al. Oxidative stress in diabetes mellitus and its complications: from pathophysiology to therapeutic strategies[J].Chin Med J (Engl), 2025, 138(1): 15-27.

[19]

Zhu L, Zhong Y, Yan M, et al. Macrophage membrane-encapsulated dopamine-modified poly cyclodextrin multifunctional biomimetic nanoparticles for atherosclerosis therapy[J].ACS Appl Mater Interfaces, 2024, 16(25): 32027-32044.

[20]

Chen S, Zhang W, Tang C, et al. Macrophage membrane-functionalized manganese dioxide nanomedicine for synergistic treatment of atherosclerosis by mitigating inflammatory storms and promoting cholesterol efflux[J].J Nanobiotechnol, 2024, 22(1): 664.

[21]

Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies[J].Cardiovasc Diabetol, 2018, 17(1): 121.

[22]

Zhou H, Wu Y, Li M, et al. Modular satellite nanoparticles for remedying primary and secondary injury in cerebral ischemia-reperfusion[J].Adv Funct Mater, 2024, 34(23): 2315274.

[23]

Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials[J].Lancet, 2023, 401(10384): 1293-1301.

[24]

Jia G, DeMarco VG, Sowers JR.Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J].Nat Rev Endocrinol, 2016, 12(3): 144-153.

[25]

Mohammadi S, Al-Harrasi A.Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy[J].World J Diabetes, 2024, 15(9): 1847-1852.

[26]

Chen P, Pan Y, Ning X, et al. Targeted heart repair by Tβ4-loaded cardiac-resident macrophage-derived extracellular vesicles modified with monocyte membranes[J].Acta Biomater, 2023, 169: 372-386.

[27]

Yin D, Zheng M, Zhang Q, et al. Macrophage membrane-modified targeted phase-change nanoparticles for multimodal imaging of experimental autoimmune myocarditis[J].Nanoscale, 2024, 16(13): 6680-6695.

[28]

Mukherjee D. Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus[J].Best Pract Res Clin Endocrinol Metab, 2009, 23(3): 335-345.

[29]

Lu S, Wang R, Cai M, et al. Platelet membrane decorated exosomes enhance targeting efficacy and therapeutic index to alleviate arterial restenosis[J].Theranostics, 2025, 15(2): 408-427.

[30]

谢环, 杨雪瑶, 宋俊华, 等. C1q 肿瘤坏死因子相关蛋白 13、摄食抑制因子 1 与 2 型糖尿病患者新发心血管疾病相关性[J].临床军医杂志, 2024, 52(7): 733-736.

基金资助

国家自然科学基金面上项目(82370457)

AI Summary AI Mindmap
PDF (2075KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉